Volume : 11, Issue : 03, March – 2024
Title:
A REVIEW ON NOVEL MEDICATION ADVANCEMENT IN THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), DIABETICS, DILATED CARDIOMYOPATHY
Authors :
G. Rajasekhar , Dr. S. Rajesh Raja
Abstract :
Drug development is the process of bringing a new drug to market after a lead chemical has been identified through drug discovery. Before a medicine is available for clinical use, the drug development process can take up to 20 years and cost as much as $3 billion USD.As we see that recent drug developments in Systemic Lupus Erythematosus (SLE). IVRADINE is a unique agent that is distinct from beta-blockers as it reduces heart rate without affecting myocardial contractility or vascular tone. The main efficacy endpoint was major adverse cardiac events (MACE) at 30 days and 6 months, defined as a composite of cardiac death, myocardial infarction, and HF hospitalizations.
Keywords: ANIFROLUMAB, TIRZETATIDE, IVABRADINE, VYMADA.
Cite This Article:
Please cite this article in press S. Rajesh Raja et al., A Review On Novel Medication Advancement In The Management Of Systemic Lupus Erythematosus (SLE), Diabetics, Dilated Cardiomyopathy., Indo Am. J. P. Sci, 2024; 11 (03).
Number of Downloads : 10
References:
1. Goldberg A, Geppert T, Schiopu E, Frech T, Hsu V, Simms RW, Peng SL, Yao Y, Elgeioushi N, Chang L, Wang B, Yoo S: Dose-escalation of human anti-interferon- alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014 Feb 24; 16(1):R57. doi: 10.1186/ar4492.
2. Peng L, Oganesyan V, Wu H, Dall’Acqua WF, Damschroder MM: Molecular basis for antagonistic activity of Anifrolumab, an anti-interferon-alpha receptor 1 antibody. MAbs. 2015;7(2):428-39. doi: 10.1080/19420862.2015.1007810.
3. Massarotti EM, Allore HG, Costenbader K: Editorial: Interferon-Targeted Therapy for Systemic Lupus Erythematosus: Are the Trials on Target? Arthritis Rheumatol. 2017 Feb; 69(2):245-248. doi: 10.1002/art.39985.
4. Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S: Anifrolumab, an Anti-Interferon-alpha Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 Feb;69(2):376-386. doi: 10.1002/art.39962.
5. Tummala R, Rouse T, Berglind A, Santiago L: Safety, tolerability and pharmacokinetics of subcutaneous and intravenous Anifrolumab in healthy volunteers. Lupus Sci Med. 2018 Mar 23;5(1):e000252. doi: 10.1136/lupus-2017-000252. eCollection 2018.
6. Riggs JM, Hanna RN, Rajan B, Zerrouki K, Karnell JL, Sagar D, Vainshtein I, Farmer E, Rosenthal K, Morehouse C, de Los Reyes M, Schifferli K, Liang M, Sanjuan MA, Sims GP, Kolbeck R: Characterization of Anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018 Apr 5;5(1):e000261. doi: 10.1136/lupus-2018-000261. eCollection 2018.
7. Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA: An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs. 2021 Jul;23(4):331-347. doi: 10.1007/s40272-021-00457-z. Epub 2021 Jul 10.
8. Ryman JT, Meibohm B: Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29.
9. Koh JWH, Ng CH, Tay SH: Biologics targeting type I interferons in SLE: A meta- analysis and systematic review of randomized controlled trials. Lupus. 2020 Dec;29(14):1845-1853. doi: 10.1177/0961203320959702. Epub 2020 Sep 22.